Clinical Trials Directory

Trials / Completed

CompletedNCT00042432

Study for Secondary Hyperparathyroidism in Chronic Renal Insufficiency Patients

A Study of an Investigational Medication for Secondary Hyperparathyroidism in Chronic Renal Insufficiency Patients

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
54 (actual)
Sponsor
Amgen · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study will assess an investigational medication for patients with chronic renal insufficiency (pre-dialysis) who have secondary hyperparathyroidism.

Conditions

Interventions

TypeNameDescription
DRUGcinacalcet (AMG 073)Initially receive 1 tablet of study medication (cinacalcet or placebo) once daily. Possible sequential dose titrations are 30, 60, 90, 120, 180mg cinacalcet or placebo) daily. The titration phase was 12 weeks and the efficacy assessment phase was 6 weeks.

Timeline

Start date
2002-06-01
Primary completion
2003-03-01
Completion
2003-08-01
First posted
2002-08-01
Last updated
2013-05-13
Results posted
2011-03-01

Source: ClinicalTrials.gov record NCT00042432. Inclusion in this directory is not an endorsement.

Study for Secondary Hyperparathyroidism in Chronic Renal Insufficiency Patients (NCT00042432) · Clinical Trials Directory